Related Experiment Video
Updated: Jan 21, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation
1Division of Cardiology, Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada.
Insights
Oral anticoagulation is key for preventing stroke in atrial fibrillation (AF) patients. Novel agents offer efficacy and safety, becoming preferred over warfarin for most AF cases, excluding artificial mechanical valves.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases stroke risk.
- Oral anticoagulation is a primary stroke prevention strategy in AF.
- Warfarin is standard for AF with mechanical valves, but newer agents are emerging.
Purpose of the Study:
- To review current evidence on stroke prevention in atrial fibrillation.
- To discuss the role of novel anticoagulants in AF management.
- To cover specific AF populations and scenarios.
Main Methods:
- Literature review of clinical trials and guidelines.
- Analysis of efficacy and safety data for anticoagulants.
- Synthesis of evidence for various AF patient subgroups.
Main Results:
- Oral anticoagulants substantially reduce stroke risk in AF.
- Novel anticoagulants demonstrate comparable or superior efficacy and safety to warfarin in non-valvular AF.
- Evidence supports anticoagulation in valvular AF, subclinical AF, renal insufficiency, and peri-cardioversion.
Conclusions:
- Novel anticoagulants are increasingly the preferred choice for stroke prevention in most AF patients.
- Warfarin remains essential for AF patients with artificial mechanical valves.
- Comprehensive stroke risk assessment guides anticoagulation decisions in AF.
Abstract:
Oral anticoagulation significantly reduces the risk of stroke in patients with atrial fibrillation (AF), and the decision to initiate therapy is based on assessing the patient's yearly risk of stroke. Although warfarin remains the drug of choice in patients with AF and artificial mechanical valves, the novel anticoagulation agents are becoming the drug of choice for all other patients with AF, because of their efficacy, safety, and ease of use. This article summarizes the current evidence for stroke prevention in AF, including valvular AF, subclinical AF, AF in patients with renal insufficiency, as well as stroke prevention around AF cardioversion.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Cancer Prevention
Some...

